Actinium Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Actinium Pharmaceuticals's earnings have been declining at an average annual rate of -19.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 11.4% per year.
Key information
-19.5%
Earnings growth rate
28.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 11.4% |
Return on equity | -97.2% |
Net Margin | -52,621.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Actinium Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -43 | 12 | 35 |
31 Mar 24 | 0 | -46 | 13 | 37 |
31 Dec 23 | 0 | -49 | 13 | 39 |
30 Sep 23 | 0 | -50 | 15 | 38 |
30 Jun 23 | 0 | -46 | 15 | 33 |
31 Mar 23 | 0 | -39 | 14 | 27 |
31 Dec 22 | 1 | -33 | 12 | 23 |
30 Sep 22 | 1 | -30 | 11 | 21 |
30 Jun 22 | 1 | -27 | 10 | 19 |
31 Mar 22 | 1 | -25 | 8 | 18 |
31 Dec 21 | 1 | -25 | 8 | 18 |
30 Sep 21 | 1 | -23 | 7 | 17 |
30 Jun 21 | 1 | -22 | 7 | 16 |
31 Mar 21 | 1 | -22 | 6 | 16 |
31 Dec 20 | 0 | -22 | 6 | 16 |
30 Sep 20 | 0 | -20 | 6 | 15 |
30 Jun 20 | 0 | -21 | 6 | 16 |
31 Mar 20 | 0 | -22 | 6 | 16 |
31 Dec 19 | 0 | -22 | 6 | 17 |
30 Sep 19 | 0 | -24 | 6 | 18 |
30 Jun 19 | 0 | -23 | 6 | 18 |
31 Mar 19 | 0 | -23 | 6 | 17 |
31 Dec 18 | 0 | -24 | 7 | 17 |
30 Sep 18 | 0 | -22 | 7 | 16 |
30 Jun 18 | 0 | -23 | 7 | 16 |
31 Mar 18 | 0 | -25 | 8 | 18 |
31 Dec 17 | 0 | -27 | 9 | 18 |
30 Sep 17 | 0 | -28 | 10 | 18 |
30 Jun 17 | 0 | -28 | 10 | 19 |
31 Mar 17 | 0 | -28 | 10 | 19 |
31 Dec 16 | 0 | -24 | 9 | 18 |
30 Sep 16 | 0 | -24 | 9 | 16 |
30 Jun 16 | 0 | -22 | 9 | 13 |
31 Mar 16 | 0 | -22 | 10 | 13 |
31 Dec 15 | 0 | -21 | 11 | 14 |
30 Sep 15 | 0 | -20 | 12 | 15 |
30 Jun 15 | 0 | -22 | 13 | 16 |
31 Mar 15 | 0 | -11 | 11 | 15 |
31 Dec 14 | 0 | -25 | 10 | 12 |
30 Sep 14 | 0 | -25 | 8 | 9 |
30 Jun 14 | 0 | -20 | 6 | 5 |
31 Mar 14 | 0 | -27 | 5 | 4 |
Quality Earnings: ATNM is currently unprofitable.
Growing Profit Margin: ATNM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATNM is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.
Accelerating Growth: Unable to compare ATNM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATNM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).
Return on Equity
High ROE: ATNM has a negative Return on Equity (-97.24%), as it is currently unprofitable.